Neoadjuvant Chemotherapy Response in Metaplastic Carcinoma of Triple Negative Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 1
- 主要终点
- response rate of neoadjuvant chemotherapy
研究概览
简要总结
prospective study for response of neoadjuvant chemotherapy in metaplastic carcinoma of triple negative breast cancer
详细描述
Vimentin/Pan CK staining will be performed on tissues of patient who visited Seoul National University Hospital and were diagnosed with triple negative breast cancer and decided to perform neoadjuvant chemotherapy under clinical judgement.
Histologically determined to be a metaplastic breast cancer or tested positive for vimentin/Pan CK patients decides as the metaplastic breast cancer. They evaluate the response rate of the neoadjuvant chemotherapy.
Patients with vimentin/Pan CK negative are diagnosed with non-metaplastic breast cancer and this group also confirms the response rate of neoadjuvant chemotherapy.
The group of metaplastic breast cancer will enroll 50 people, and the group of non-metaplastic breast cancer will enroll 100 people.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •over 20 years old
- •patients with triple negative breast cancer diagnosed Seoul National University Hospital
- •patients who decided to perform neoadjuvant chemotherapy under clinical judgement
排除标准
- •not applicable
结局指标
主要结局
response rate of neoadjuvant chemotherapy
时间窗: After neoadjuvant chemotherapy was finished. Average 6 month later.
response criteria for neoadjuvant chemotherapy-complete response (CR), partial response (PR), and no response (NR)
次要结局
未报告次要终点
研究者
Hyeong-Gon Moon
Medical doctor, Clinical Professor
Seoul National University Hospital